Novato, CA, June 18, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a
biopharmaceutical company focused on the development of novel
products for rare and ultra-rare diseases, today announced that
Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer,
will be presenting at the JMP Securities Healthcare Conference on
June 25, 2014 at 2:30pm ET at the Westin New York Grand
The live and archived webcast of the company presentation will
be accessible from the company's website at http://ir.ultragenyx.com/events.cfm.
The replay of the webcast will be available approximately one hour
after the conclusion of the live presentation and will be available
for 180 days.
Ultragenyx is a development-stage biopharmaceutical company
committed to bringing to market novel products for the treatment of
rare and ultra-rare diseases, with an initial focus on serious,
debilitating genetic diseases. Founded in 2010, the company has
rapidly built a diverse portfolio of product candidates with the
potential to address diseases for which the unmet medical need is
high, the biology for treatment is clear, and for which there are
no approved therapies.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx's strategy is predicated upon time and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at www.ultragenyx.com.
CONTACT: Contact Ultragenyx Pharmaceutical Inc.
For Media, Bee NguyenFor Investors, Robert Anstey
Source: Ultragenyx Pharmaceutical Inc.